National Medical Care Future Growth
Future criteria checks 2/6
National Medical Care is forecast to grow earnings and revenue by 12.2% and 12% per annum respectively. EPS is expected to grow by 11.4% per annum. Return on equity is forecast to be 20% in 3 years.
Key information
12.2%
Earnings growth rate
11.4%
EPS growth rate
Healthcare earnings growth | 14.0% |
Revenue growth rate | 12.0% |
Future return on equity | 20.0% |
Analyst coverage | Good |
Last updated | 11 Mar 2025 |
Recent future growth updates
Recent updates
National Medical Care (TADAWUL:4005) Might Have The Makings Of A Multi-Bagger
Jan 30If EPS Growth Is Important To You, National Medical Care (TADAWUL:4005) Presents An Opportunity
Jan 08What National Medical Care Company's (TADAWUL:4005) P/E Is Not Telling You
Dec 12National Medical Care's (TADAWUL:4005) Solid Earnings May Rest On Weak Foundations
Oct 29National Medical Care (TADAWUL:4005) Shareholders Will Want The ROCE Trajectory To Continue
Sep 25Analysts Are Updating Their National Medical Care Company (TADAWUL:4005) Estimates After Its Second-Quarter Results
Aug 06Getting In Cheap On National Medical Care Company (TADAWUL:4005) Is Unlikely
Jul 26National Medical Care Company's (TADAWUL:4005) Shares May Have Run Too Fast Too Soon
Apr 05We Think National Medical Care's (TADAWUL:4005) Robust Earnings Are Conservative
Mar 14National Medical Care (TADAWUL:4005) Is Very Good At Capital Allocation
Mar 13Some Confidence Is Lacking In National Medical Care Company's (TADAWUL:4005) P/E
Dec 27Returns On Capital Are Showing Encouraging Signs At National Medical Care (TADAWUL:4005)
Dec 05We Like These Underlying Return On Capital Trends At National Medical Care (TADAWUL:4005)
Aug 07Is National Medical Care Company (TADAWUL:4005) Worth ر.س107 Based On Its Intrinsic Value?
May 29Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
May 08Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
Dec 19A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Oct 19National Medical Care (TADAWUL:4005) Is Doing The Right Things To Multiply Its Share Price
Aug 15National Medical Care's (TADAWUL:4005) Returns On Capital Are Heading Higher
May 13Earnings Update: National Medical Care Company (TADAWUL:4005) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 03A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Feb 10Returns At National Medical Care (TADAWUL:4005) Appear To Be Weighed Down
Nov 10Returns On Capital At National Medical Care (TADAWUL:4005) Have Hit The Brakes
Jul 02Estimating The Intrinsic Value Of National Medical Care Company (TADAWUL:4005)
Apr 14Is National Medical Care Company (TADAWUL:4005) A Risky Dividend Stock?
Mar 25Will National Medical Care (TADAWUL:4005) Multiply In Value Going Forward?
Feb 23Update: National Medical Care (TADAWUL:4005) Stock Gained 25% In The Last Five Years
Feb 09National Medical Care Company's (TADAWUL:4005) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Jan 27Calculating The Fair Value Of National Medical Care Company (TADAWUL:4005)
Jan 14Is National Medical Care Company's (TADAWUL:4005) 3.8% Dividend Sustainable?
Dec 25Does National Medical Care's (TADAWUL:4005) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 10What Kind Of Shareholders Hold The Majority In National Medical Care Company's (TADAWUL:4005) Shares?
Nov 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 1,898 | 419 | 286 | 486 | 4 |
12/31/2026 | 1,758 | 371 | 222 | 425 | 6 |
12/31/2025 | 1,528 | 308 | 109 | 326 | 6 |
12/31/2024 | 1,294 | 298 | 245 | 245 | N/A |
9/30/2024 | 1,221 | 274 | -322 | -85 | N/A |
6/30/2024 | 1,171 | 288 | -134 | 88 | N/A |
3/31/2024 | 1,119 | 266 | 212 | 423 | N/A |
12/31/2023 | 1,082 | 241 | 412 | 467 | N/A |
9/30/2023 | 1,034 | 233 | 838 | 704 | N/A |
6/30/2023 | 997 | 202 | 670 | 531 | N/A |
3/31/2023 | 968 | 196 | 349 | 386 | N/A |
12/31/2022 | 918 | 170 | 185 | 217 | N/A |
9/30/2022 | 882 | 151 | -162 | 52 | N/A |
6/30/2022 | 857 | 142 | -126 | 86 | N/A |
3/31/2022 | 843 | 131 | 8 | 45 | N/A |
12/31/2021 | 845 | 136 | 56 | 94 | N/A |
9/30/2021 | 844 | 122 | 58 | 94 | N/A |
6/30/2021 | 845 | 105 | 15 | 49 | N/A |
3/31/2021 | 828 | 100 | 17 | 40 | N/A |
12/31/2020 | 809 | 97 | 88 | 107 | N/A |
9/30/2020 | 780 | 95 | 187 | 198 | N/A |
6/30/2020 | 740 | 95 | 216 | 225 | N/A |
3/31/2020 | 724 | 83 | 155 | 162 | N/A |
12/31/2019 | 708 | 80 | 152 | 162 | N/A |
9/30/2019 | 705 | 65 | 236 | 246 | N/A |
6/30/2019 | 707 | 60 | 245 | 259 | N/A |
3/31/2019 | 737 | 67 | 188 | 206 | N/A |
12/31/2018 | 764 | 62 | 299 | 318 | N/A |
9/30/2018 | 810 | 81 | N/A | 231 | N/A |
6/30/2018 | 842 | 96 | N/A | 236 | N/A |
3/31/2018 | 859 | 95 | N/A | 279 | N/A |
12/31/2017 | 855 | 85 | N/A | 113 | N/A |
9/30/2017 | 817 | -8 | N/A | -9 | N/A |
6/30/2017 | 806 | -7 | N/A | 70 | N/A |
3/31/2017 | 849 | 33 | N/A | 72 | N/A |
12/31/2016 | 901 | 50 | N/A | 103 | N/A |
9/30/2016 | 931 | 155 | N/A | 87 | N/A |
6/30/2016 | 945 | 153 | N/A | 63 | N/A |
3/31/2016 | 913 | 136 | N/A | 77 | N/A |
12/31/2015 | 879 | 131 | N/A | 51 | N/A |
9/30/2015 | 853 | 106 | N/A | 127 | N/A |
6/30/2015 | 820 | 102 | N/A | 80 | N/A |
3/31/2015 | 772 | 91 | N/A | 38 | N/A |
12/31/2014 | 734 | 95 | N/A | 71 | N/A |
9/30/2014 | 703 | 106 | N/A | 32 | N/A |
6/30/2014 | 660 | 103 | N/A | 15 | N/A |
3/31/2014 | 623 | 94 | N/A | 75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4005's forecast earnings growth (12.2% per year) is below the savings rate (14.9%).
Earnings vs Market: 4005's earnings (12.2% per year) are forecast to grow faster than the SA market (6.4% per year).
High Growth Earnings: 4005's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4005's revenue (12% per year) is forecast to grow faster than the SA market (1.3% per year).
High Growth Revenue: 4005's revenue (12% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4005's Return on Equity is forecast to be low in 3 years time (20%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/12 11:24 |
End of Day Share Price | 2025/03/12 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
National Medical Care Company is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ibrahim Elaiwat | Aljazira Capital Company |
Jassim Al-Jubran | Aljazira Capital Company |
Madhu Appissa | Al Rajhi Capital |